Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma

Abstract

Summary High expression of the inhibitory receptor programmed cell death ligand 1 (PD‐L1) on tumor cells and tumor stromal cells have been found to play a key role in tumor immune evasion in several human malignancies. However, the expression of PD‐L1 on bone marrow mesenchymal stem cells (BMSCs) and whether the programmed cell death 1 (PD‐1)/PD‐L1 signal pathway is involved in the BMSCs versus T cell immune response in multiple myeloma (MM) remains poorly defined. In this study, we explored the expression of PD‐L1 on BMSCs from newly diagnosed MM (NDMM) patients and the role of PD‐1/PD‐L1 pathway in BMSC‐mediated regulation of CD8+ T cells. The data showed that the expression of PD‐L1 on BMSCs in NDMM patients was significantly increased compared to that in normal controls (NC) (18·81 ± 1·61 versus 2·78± 0·70%; P < 0·001). Furthermore, the PD‐1 expression on CD8+ T cells with NDMM patients was significantly higher than that in normal controls (43·22 ± 2·98 versus 20·71 ± 1·08%; P < 0·001). However, there was no significant difference in PD‐1 expression of CD4+ T cells and natural killer (NK) cells between the NDMM and NC groups. Additionally, the co‐culture assays revealed that BMSCs significantly suppressed CD8+ T cell function. However, the PD‐L1 inhibitor effectively reversed BMSC‐mediated suppression in CD8+ T cells. We also found that the combination of PD‐L1 inhibitor and pomalidomide can further enhance the killing effect of CD8+ T cells on MM cells. In summary, our findings demonstrated that BMSCs in patients with MM may induce apoptosis of CD8+ T cells through the PD‐1/PD‐L1 axis and inhibit the release of perforin and granzyme B from CD8+ T cells to promote the immune escape of MM.

Do regional government green innovation preferences promote industrial structure upgradation in China? Econometric assessment based on the environmental regulation threshold effect model

“…This shift effects GGIP (lnGR) in a manner that (rather than supporting) it inhibits the advancement of ISU (TS) to the next stage. Consistent with the previous studies (e.g., Liu & Wang, 2021), the FE coefficient indicated the following effects of different variables on ISU (TS) at 1% significance: insignificant (financial investments, FN = 0.0449, Ln GDP = 0.449); negative (infrastructure, ln INF = -0.1962, degree of openness, lnOP = -0.0809), and positive (human capital level, lnHC = 0.3690).…”

Exosomal miR-483-5p in Bone Marrow Mesenchymal Stem Cells Promotes Malignant Progression of Multiple Myeloma by Targeting TIMP2

“…The bone marrow microenvironment consists of different types of cells, and bone marrow mesenchymal stem cell (BMSC) is the leading stem cell type in human bone marrow ( Weinberg, 2008 ; Zahn, 2017 ; Dart, 2018 ; Nwabo Kamdje et al, 2020 ). BMSCs play an essential role in the malignant progression of hematologic diseases, including MM ( Jin et al, 2019 ; Lee et al, 2019 ; Liu et al, 2021 ). BMSCs interact with other cells by cell-to-cell contacts and secretion of soluble factors.…”

Human placenta‐derived mesenchymal stem cells ameliorate diabetic kidney disease by modulating the T helper 17 cell/ regulatory T‐cell balance through the programmed death 1 / programmed death‐ligand 1 pathway

“…PD‐1, an important immunosuppressive molecule, has been increasingly studied in the immunomodulatory effects of MSCs. Evidence has confirmed that MSCs regulate T‐cell activation, proliferation, and differentiation through the PD1/PD‐L1 signalling pathway 38,39 . For example, Zhou et al reported that adipose‐derived MSCs significantly suppressed the T‐cell proliferation and IFN‐γ production, accompanied by upregulated PD‐1/PD‐L1 expression during MSCs co‐culture with T cells, and this inhibition was markedly attenuated by PD‐L1 blockade 39 .…”